Bruce A. Silver

544 total citations
15 papers, 296 citations indexed

About

Bruce A. Silver is a scholar working on Hematology, Physiology and Molecular Biology. According to data from OpenAlex, Bruce A. Silver has authored 15 papers receiving a total of 296 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hematology, 5 papers in Physiology and 4 papers in Molecular Biology. Recurrent topics in Bruce A. Silver's work include Erythrocyte Function and Pathophysiology (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Angiogenesis and VEGF in Cancer (3 papers). Bruce A. Silver is often cited by papers focused on Erythrocyte Function and Pathophysiology (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Angiogenesis and VEGF in Cancer (3 papers). Bruce A. Silver collaborates with scholars based in United States, United Kingdom and Netherlands. Bruce A. Silver's co-authors include Lisa Fichtel, Cheryl A. Eaton, David A. Reardon, Thomas Coyle, Santosh Kesari, Monica Mita, Eric S. Furfine, John de Groot, Jochem Gokemeijer and Alain C. Mita and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

Bruce A. Silver

14 papers receiving 279 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bruce A. Silver United States 8 117 84 83 75 42 15 296
Eui-Jong Kwon South Korea 3 115 1.0× 32 0.4× 23 0.3× 73 1.0× 16 0.4× 7 365
Petra Bohanec Grabar Slovenia 9 75 0.6× 14 0.2× 103 1.2× 73 1.0× 13 0.3× 11 413
Tamer Zeren United States 9 127 1.1× 46 0.5× 21 0.3× 108 1.4× 11 0.3× 16 343
Hiroo Makimoto Japan 13 161 1.4× 28 0.3× 12 0.1× 90 1.2× 16 0.4× 32 346
Guowei Dai China 9 268 2.3× 19 0.2× 55 0.7× 68 0.9× 8 0.2× 18 451
Weiguo Xiao China 14 120 1.0× 11 0.1× 28 0.3× 75 1.0× 63 1.5× 33 468
Rebecca E. Parker United States 12 179 1.5× 22 0.3× 25 0.3× 70 0.9× 20 0.5× 23 398
Eva Brčáková Czechia 13 94 0.8× 8 0.1× 44 0.5× 127 1.7× 52 1.2× 20 366
Emilia Pardal Spain 8 99 0.8× 34 0.4× 73 0.9× 54 0.7× 5 0.1× 13 276
Yang Ym China 9 121 1.0× 13 0.2× 68 0.8× 55 0.7× 12 0.3× 22 339

Countries citing papers authored by Bruce A. Silver

Since Specialization
Citations

This map shows the geographic impact of Bruce A. Silver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce A. Silver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce A. Silver more than expected).

Fields of papers citing papers by Bruce A. Silver

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce A. Silver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce A. Silver. The network helps show where Bruce A. Silver may publish in the future.

Co-authorship network of co-authors of Bruce A. Silver

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce A. Silver. A scholar is included among the top collaborators of Bruce A. Silver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce A. Silver. Bruce A. Silver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
3.
Grace, Rachael F., D. Mark Layton, Frédéric Galactéros, et al.. (2017). Results Update from the DRIVE PK Study: Effects of AG-348, a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency. Blood. 130. 2194–2194. 2 indexed citations
4.
5.
Schiff, David, Santosh Kesari, John de Groot, et al.. (2014). Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. Investigational New Drugs. 33(1). 247–253. 42 indexed citations
6.
7.
Westlin, William, Heather Lounsbury, Bruce A. Silver, et al.. (2012). Abstract 1745: Translational medicine enables rapid early clinical development of AVL-292, a highly selective, orally available inhibitor of Bruton's tyrosine kinase, in a phase 1b clinical trial. Cancer Research. 72(8_Supplement). 1745–1745. 4 indexed citations
8.
Brown, Jennifer R., Jeff P. Sharman, Wael A. Harb, et al.. (2012). Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).. Journal of Clinical Oncology. 30(15_suppl). 8032–8032. 29 indexed citations
9.
Tolcher, Anthony W., Christopher J. Sweeney, K. Papadopoulos, et al.. (2011). Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin. Clinical Cancer Research. 17(2). 363–371. 67 indexed citations
10.
Reardon, David A., Santosh Kesari, T. Mikkelsen, et al.. (2010). Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM).. Journal of Clinical Oncology. 28(15_suppl). 2011–2011. 13 indexed citations
11.
Mita, Monica, Kyriakos P. Papadopoulos, Bruce A. Silver, et al.. (2008). Phase I study of CT-322, first Adnectin protein therapeutic and potent inhibitor of VEGFR-2, in patients (pts) with advanced solid tumors (ST). Journal of Clinical Oncology. 26(15_suppl). 3523–3523. 8 indexed citations
12.
Stadtmauer, Edward A., David S. Siegel, Dan T. Vogl, et al.. (2008). A Phase 1 Trial of Fluphenazine HCl (Fz), a Serotonin Antagonist, in Relapsed and Refractory Multiple Myeloma. Blood. 112(11). 5188–5188. 2 indexed citations
13.
14.
Fisher, Richard I., et al.. (1982). Objective regressions of T- and B-cell lymphomas in patients following treatment with anti-thymocyte globulin.. PubMed. 42(6). 2465–9. 9 indexed citations
15.
Silver, Bruce A., et al.. (1979). Cimetidine Potentiation of the Hypoprothrombinemic Effect of Warfarin. Annals of Internal Medicine. 90(3). 348–349. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eui-Jong Kwon Breakdown of academic impact, for papers by Petra Bohanec Grabar Breakdown of academic impact, for papers by Tamer Zeren Breakdown of academic impact, for papers by Hiroo Makimoto Breakdown of academic impact, for papers by Guowei Dai Breakdown of academic impact, for papers by Weiguo Xiao Breakdown of academic impact, for papers by Rebecca E. Parker Breakdown of academic impact, for papers by Eva Brčáková Breakdown of academic impact, for papers by Emilia Pardal Breakdown of academic impact, for papers by Yang Ym
Rankless by CCL
2026